title: PD-L1 inhibition with MPDL3280A for solid tumors.
abstract: Cancer immunotherapy has become a popular anticancer approach, with the goal of stimulating immune responses against tumor cells. Recent evidence has demonstrated that the use of monoclonal antibodies targeting the programmed death ligand-1 (PD-L1)/programmed death-1 (PD-1) checkpoint pathway can result in well-tolerated clinical responses in a wide variety of tumor types. This review summarizes the safety, clinical activity and biomarker data for the anti-PD-L1 antibody, MPDL3280A, from a phase Ia multicenter, dose-escalation and -expansion trial. The data to date suggest that MPDL3280A is most effective in patients with pre-existing immunity suppressed by PD-L1 and reinvigorated upon antibody treatment.
authors.affiliation: Product Development Oncology, Genentech, Inc, South San Francisco, CA. Electronic address: cha.edward@gene.com.
authors.forename: Edward
authors.initials: E
authors.lastname: Cha
authors.affiliation: Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Wallin
authors.affiliation: Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA.
authors.forename: Marcin
authors.initials: M
authors.lastname: Kowanetz
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004357:Drug Synergism; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; C423236:CD274 protein, human; C000594389:atezolizumab